344 related articles for article (PubMed ID: 31929122)
1. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J
J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122
[TBL] [Abstract][Full Text] [Related]
2. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Hauser RA; Pahwa R; Tanner CM; Oertel W; Isaacson SH; Johnson R; Felt L; Stempien MJ
J Parkinsons Dis; 2017; 7(3):511-522. PubMed ID: 28777755
[TBL] [Abstract][Full Text] [Related]
3. Amantadine Extended-Release (GOCOVRI
Paik J; Keam SJ
CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
[TBL] [Abstract][Full Text] [Related]
4. Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.
Mehta SH; Pahwa R; Tanner CM; Hauser RA; Johnson R
Neurol Ther; 2021 Jun; 10(1):307-320. PubMed ID: 33864229
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Hauser RA; Kremens DE; Elmer LW; Kreitzman DL; Walsh RR; Johnson R; Howard R; Nguyen JT; Patni R
J Parkinsons Dis; 2019; 9(3):591-600. PubMed ID: 31081793
[TBL] [Abstract][Full Text] [Related]
6. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
[TBL] [Abstract][Full Text] [Related]
7. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
8. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Elmer LW; Juncos JL; Singer C; Truong DD; Criswell SR; Parashos S; Felt L; Johnson R; Patni R
CNS Drugs; 2018 Apr; 32(4):387-398. PubMed ID: 29532440
[TBL] [Abstract][Full Text] [Related]
9. Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia.
Hauser RA; Mehta SH; Kremens D; Chernick D; Formella AE
Neurol Ther; 2021 Dec; 10(2):739-751. PubMed ID: 34024025
[TBL] [Abstract][Full Text] [Related]
10. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Pahwa R; Tanner CM; Hauser RA; Isaacson SH; Nausieda PA; Truong DD; Agarwal P; Hull KL; Lyons KE; Johnson R; Stempien MJ
JAMA Neurol; 2017 Aug; 74(8):941-949. PubMed ID: 28604926
[TBL] [Abstract][Full Text] [Related]
11. GOCOVRI
Müller T
Neurodegener Dis Manag; 2022 Feb; 12(1):15-28. PubMed ID: 34918543
[TBL] [Abstract][Full Text] [Related]
12. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O; Tönges L; deVries T; Jaros M; Quartel A; Jacobs D;
Parkinsonism Relat Disord; 2022 Mar; 96():65-73. PubMed ID: 35227940
[TBL] [Abstract][Full Text] [Related]
13. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Pajo AT; Espiritu AI; Jamora RDG
Neurodegener Dis Manag; 2019 Aug; 9(4):205-215. PubMed ID: 31392922
[No Abstract] [Full Text] [Related]
15. Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Med Lett Drugs Ther; 2017 Dec; 59(1535):198-200. PubMed ID: 29186084
[No Abstract] [Full Text] [Related]
16. Subthalamic nucleus deep brain stimulation improves dyskinesias in Parkinson's disease beyond levodopa reduction.
Mossner JM; Patil PG; Chou KL
J Neural Transm (Vienna); 2019 Nov; 126(11):1479-1483. PubMed ID: 31494731
[TBL] [Abstract][Full Text] [Related]
17. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Elkurd MT; Bahroo LB; Pahwa R
Neurodegener Dis Manag; 2018 Apr; 8(2):73-80. PubMed ID: 29564954
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
Isaacson SH; Fahn S; Pahwa R; Tanner CM; Espay AJ; Trenkwalder C; Adler CH; Patni R; Johnson R
Mov Disord Clin Pract; 2018; 5(2):183-190. PubMed ID: 29780852
[TBL] [Abstract][Full Text] [Related]
19. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
20. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
